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Abstract: 27 
 28 
Viruses are obligate parasites of host cells. The virus/host coevolution has selected virus for 29 
growth despite antiviral defences set up by hosting cells and organisms. Ubiquitin conjugation 30 
onto proteins, through a cascade of reaction mediated by the E1 ubiquitin activating enzyme, E2 31 
and E3 ubiquitin conjugating ligases, is one of the major regulatory system which, in particular, 32 
tightly control the concentration of cellular proteins by sorting them for degradation. The 33 
combined diversity of E2 and E3 ligases ensures the selective/specific ubiquitination of a large 34 
number of protein substrates within the cell interior. Therefore it is not surprising that several 35 
viruses are coding proteins with E3 ubiquitin ligase activities to target cellular proteins which play 36 
a key role in the innate antiviral mechanisms. 37 
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Introduction 42 
 43 
Viruses have evolved to sneak through the innate and adaptive antiviral response both at 44 
the cellular and whole organism levels, for survival and successful infection spreading (29, 38, 45 
57). Most aspects of the life cycle of viruses critically rely on the specific interaction between viral 46 
and host cell proteins to redirect the cellular metabolism for their benefit. Post-translationally 47 
polypeptide tagging by the conjugation of ubiquitin (ubiquitination), sumo (sumoylation), Nedd8 48 
(neddylation) and ISG15 (ISGylation) (52, 124) is a potent way to alter protein function and/or to 49 
sort protein. The ubiquitin-proteasome system is a mandatory player in many regulatory 50 
processes in mammalian cells (39). Monoubiquitination of proteins are sorted and 51 
polyubiqitinated proteins are targeted for degradation into small peptides by the 26S proteasome. 52 
The latter is necessary to ensure efficient turn-over of most cellular proteins. Elegantly, the 53 
evolution has selected for the screening of short peptides derived from proteasome degradation 54 
as a read-out of self integrity via the MHC class I presentation pathway to CD8 T lymphocytes.  55 
Ubiquitin (Ub) is a conserved 76 amino acid polypeptide when attached to a protein 56 
mediates interaction with other proteins (53). Ubiquitin conjugation to a substrate involves a 57 
cascade of at least three different enzymatic reactions. In the first step, the ubiquitin binds to the 58 
C-terminus of E1 activating enzyme by a thioester linkage through an energy-requiring process. 59 
In the second step, activated Ub is transferred, again through a thioester linkage, to an ubiquitin 60 
conjugating enzyme E2 (Ubc) or E2 ligase. In the third step, the activated ubiquitin is transferred 61 
from the E2 thioester linkage to a lysine residue of the target protein, through a peptide-bond onto 62 
the side chain, resulting in a branched peptide. This last step is catalyzed by an Ubc E3 or E3 63 
ligase, which specifically recognizes the substrate proteins. Ubiquitination can reversibly take 64 
place through the action of deubiquitinating (DUBs) enzymes, which remove ubiquitin chains from 65 
specific ubiquitin-protein conjugates (5, 23, 53, 124). Thus ubiquitination follows dynamic forward 66 
and backward processes. In human, the Ub enzymatic players are unique for E1, over 50 for E2 67 
and several hundreds for E3. The large number of E2 and E3 ligases and their combination 68 
ensures the necessary specific and individual targeting of thousands of different proteins.  69 
Structurally and functionally, E3 ligases are heterogeneous. One group, which includes 70 
the Nedd4 family, is characterized by the presence of the homology to the E6-associated protein 71 
carboxyl terminus (HECT) catalytic domain, (58). These are the only catalytic E3 ligases on which 72 
activated Ub is transferred from E2, again through a thioester bond, before Ubiquitin transfer to 73 
the target substrate through a peptide bond. The prototype is the E6-associated protein (E6-AP). 74 
The second group acts only as a linker or a scaffold to bring specific substrates near Ub charged 75 
E2 ligase closer enough to enable the Ub transfer from E2 to a Lys residue of the substrate. This 76 
group can be subdivided into unimolecular and multimolecular E3 ligases. Unimolecular linker-77 
type E3 ligases contain a Zn-finger called the really interesting new gene (RING) domain which 78 
recruits E2 enzymes. RING domains are closely related to PHD domains (or PHD fingers) and 79 
the frontier is disputed among the structuralists, the issue of which is the prediction of E3 ligase 80 
activity (109). The U-box is found as an alternative to the RING domain. U-box is predicted to be 81 
structurally related, but lack the hallmark metal-chelating residues (50). The prototype of 82 
unimolecular RING E3 ligase is MDM2, the major E3 ligase of p53. The multicomponent E3 83 
ligases contain a variable number of subunits with at least one subunit characterised by the 84 
presence of a RING domain and a complex containing one Cullin protein. The RING domain is 85 
responsible for the recruitment of E2 and the Cullin complex acts as a scaffold for the recognition 86 
of specific substrates. Prototypes of multisubunit E3 ligases are the SCF (4) and anaphase 87 
promoting complex/cyclosome (APC/C) complex (17).  88 
Because of the necessary continuous adaptation of viruses to their hosts, it is not 89 
surprising that viruses can modify the ubiquitin-proteasome machinery of host cells and use it for 90 
their own profit. So far, this modulation process takes place at the E3 ligase level i.e. at the step 91 
where the substrate specificity is critically defined. Some viral proteins acts as E3 ligases, and 92 
other redirect host ubiquitin E3 ligases to target new substrate proteins (5). Viral E3 ligases are 93 
involved in the regulation of many aspects of viral and cellular processes such as virus budding, 94 
cell division, apoptosis, antigen presentation, lymphocyte activation, induction of T cell-tolerance, 95 
immune evasion, and innate immunity to list a few (5, 75). 96 
  97 
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  The scope of this review is to focus on viral hijacking of Ubiquitin ligases to modulate 98 
cellular intrinsic antiviral activities and innate immunity. Based on a classification of E3 ligase 99 
according to their catalytic/non catalytic activity, and on their unimolecular or multisubunit 100 
structure, the following viral ubiquitin E3 ligases will be reviewed: RTA, a novel unimolecular 101 
catalytic E3 ligase, E6, a E3 ligase able to hijack another (catalytic) E3 ligase, ICP0 a 102 
bifunctionnal unimolecular RING-type E3 ligase, E4orf6/E1B55K and VIF, two RING/Cullin E3 103 
ligase “BC-box” subunits, and V, a RING/Cullin E3 ligase subunit with a new Zn-finger motif. 104 
 105 
 106 
1) Kaposi sarcoma associated herpesvirus RTA protein: an unimolecular viral catalytic E3 107 
ligase  108 
 109 
 Kaposi sarcoma associated herpesvirus, KSHV, is a DNA tumour virus that cause rare 110 
endothelial and lymphoid tumour mostly in immunocompromised patients. The viral RTA protein 111 
is a DNA binding nuclear transcription factor acting throughout the virus replication cycle.  112 
 113 
Gene and structure 114 
KSHV Orf50 codes an protein of 691 amino acid length, called RTA, which is a homolog 115 
of the RTA protein coded by Epstein Barr virus, another oncogenic herpesviridae (116). It was 116 
found to bind to IRF7 during a yeast two hybrid screening of a human cDNA library. 117 
 118 
E3 ligase activities 119 
RTA amino-terminal half-part binds to IRF7 (FIGURE 1) and induces its polyubiquitination 120 
and degradation by the proteasome. In vitro, RTA acts as a unimolecular E3 ligase for 121 
ubiquitination of IRF7 in the presence of the Ubch5α E2 ligase, E1 and ubiquitin. RTA also 122 
recognises itself as a substrate for polyubiquitination. RTA has a Cys-rich region of a novel type 123 
which is proposed to harbour the intrinsic catalytic E3 ligase activity. Indeed mutations of key Cys 124 
or His residues within this region result in the loss of E3 ligase activity of RTA without hampering 125 
its binding to IRF7 (127). 126 
 127 
Cellular impact and counteraction of innate immunity 128 
Besides the key role of RTA in the positive regulation of viral transcription (see (127) and 129 
references therein), RTA is predicted to counteract the innate immunity by preventing the 130 
activation of IFN-α gene. Indeed IRF7 is a key transactivator of this gene (95). Interestingly, 131 
KSHV code for at least two other proteins with E3 ligase activity, MIR1 and MIR2. They are 132 
involved in the regulation of the adaptative immunity, because they target MHC class I molecules 133 
for degradation (24). 134 
 135 
 136 
2) Human papillomavirus E6 protein: hijacker of a unimolecular E3 ligase 137 
 138 
The high risk human papillomaviruses (e.g. HPV-16 and HPV-18) are causative agents of 139 
cervical cancers. Their oncogenic properties correlate with the transforming activities of the viral 140 
oncogenes E6 and E7. Both of them use the ubiquitin-proteasome system to target a variety of 141 
important negative cell regulatory proteins. E7 protein upregulates proliferation-related genes by 142 
interacting with the retinoblastoma protein  pRb, and related protein p107 et p130 (31), (see also 143 
(5, 110) for review). E6 circumvents the cell apoptotic response to uncontrolled cell proliferation 144 
by binding to p53 (123), see also (67) for review.  145 
 146 
Genes and structures 147 
E6 and E7 are two early transcribed genes located first after the unique viral transcription 148 
promoter. E6 and E7 are relatively small proteins with a size of about one hundred and one 149 
hundred and fifty amino acids, respectively. Non oncogenic HPVs differ from the oncogenic HPV-150 
16 and HPV18 by encoding E6 and E7 proteins poorly efficient in recruiting their cellular targets 151 
for degradation by the ubiquitin and proteasome pathway (26, 41, 107). 152 
 153 
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E3 ligase activities 154 
E6 protein displays two types of E3 ligase activities according to the involvement or not of 155 
the cellular E6-AP protein (FIGURE 2).  156 
E6-AP dependent E3 ligase  157 
On one hand, E6 binds through its N-terminus to the unimolecular E6-AP E3 ligase. E6-158 
AP contains an active enzymatic HECT site which interacts with several E2 conjugating enzymes, 159 
including UbcH5, UbcH6, UbcH7 and UbcH8 (see (110) for review). On the other hand, E6 160 
recruits many cellular proteins as substrates for ubiquitination. 161 
E6 oncoprotein promotes the degradation of p53 through its interaction with E6-AP to 162 
form an E3 ubiquitin ligase complex (55, 117) (see also (110) for review). Firstly, E6 associates 163 
with E6-AP, secondly, the dimeric E6/E6-AP complex binds to p53 and induces E6-AP-mediated 164 
ubiquitination of p53, and thirdly, polyubiquitinated p53 is recognized and degraded by 26S 165 
proteasome (see (110) for review). E6 association with E6-AP likely alters its substrate specificity 166 
because E6-AP itself is unable to recognize p53 as a target for ubiquitination (117). Conversely, 167 
does E6 binding to E6-AP prevent its activity on normally E6-independent substrates ? The 168 
precise scaffold of the E6/E6-AP/p53 complex is yet to be uncovered. It is proposed that a small 169 
helical domain within E6-AP (L2G motif), which binds to E6, also associates with p53 (56), and 170 
E6 binds to the core DNA-binding domain of p53 (44, 96). Strikingly, the effect of E6 on p53 is 171 
independent of the six C-terminal lysine residues in p53, which are critical for effective 172 
ubiquitination mediated by the physiological cellular unimolecular RING-type E3 ligase Mdm2 173 
(15). 174 
HPV E6 proteins also promote the E6-AP-dependent degradation of many other proteins 175 
(see (37, 110) for review) that are independent of p53 degradation, including E6-AP (59), the 176 
human homolog of the Drosophila melanogaster tumor suppressor Discs large (hDLG), the 177 
human homolog of the Drosophila Scribble (Vartul), the apoptosis-promoting Bak protein, a novel 178 
GAP protein called E6TP1, MAG-1, the DNA repair protein, O(6)-methylguanine-DNA 179 
methyltransferase MGMT, MUPP-1, the GAIP(GTPase-activating protein for GαI)- interacting 180 
protein C terminus TIP2/GIPC (36) and two PDZ containing proteins, hScrib, a tumor suppressor 181 
protein, and NFX1-91, a cellular repressor of human hTERT (the catalytic and rate-limiting 182 
subunit of telomerase) (72). E6 also binds to, and can ubiquitinate c-Myc (42), although this latter 183 
event is not observed in physiological conditions (122).  184 
E6-AP independent E3 ligase  185 
E6 is also an E3 ligase in the absence of E6-AP for several substrates including Blk, a 186 
member of the Src-family of non-receptor tyrosine kinase, Bak, a human proapoptotic protein, 187 
Mcm7 and two human homologues of the yeast DNA repair protein RAD23, HHR23A and 188 
HHR23B. The mechanism by which E6 targets proteins for degradation in an E6-AP-independent 189 
manner is presently unclear (see (5, 110) for review). 190 
Cellular partners but not substrates of E3 ligase 191 
E6 interacts with another set of cellular proteins without evidence for ubiquitination and 192 
degradation including E6-BP (21), CBP/p300 (94, 130), Tyk2 (65), the transcriptional integrator of 193 
the E2F1/DP1/RB cell-cycle regulatory pathway TRIP-Br1 (45) and IRF-3 (103). The binding site 194 
of these partners are unknown, but there is evidence for multiple binding sites on P6 including its 195 
PDZ binding domain. 196 
E7 protein: a substrate recruiting sub-unit of an E3 ligase? 197 
The ability of oncogenic HPVs to target cellular proteins for proteasome-mediated 198 
degradation is not restricted to E6. E7 is a substrate for the UbcH7 E2 and Cul1-Skp2 containing 199 
E3 ligases (89). E7 binds to pRb and related proteins (5, 110) and induces their ubiquitination and 200 
degradation by the 26S proteasome. These data suggest that E7 may also act as a substrate 201 
recruiting sub-unit of a complex E3 ligase. 202 
 203 
Cellular impact and counteraction of innate immunity 204 
 Besides their strong impact on the cell cycle control, apoptosis and oncogenic properties 205 
which are the subject of intensive work, E6 and E7 proteins exhibit multiple anti-interferon 206 
activities (62). Surprisingly the inhibitory effect of E6 and E7 is not related with their ability to 207 
target cellular protein for ubiquitination and degradation. E6 binds to CBP, P300 and IRF-3 and 208 
inhibits their transcriptional activity (94, 103). Since IRF3 and CBP/p300 are cooperative subunits 209 
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of the IFN-β enhanceosome  expression of E6 blocks IFN-β gene activation upon viral infection 210 
(103). E6 binds to Tyk-2 and competes for Tyk-2 binding to the interferon receptor subunit 211 
IFNAR1. Thus, E6 inhibits the downstream activation of the Jak-STAT1-STAT2 pathway (65), and 212 
cells poorly respond to exogenous IFN treatment. Further downstream of this pathway, E7 binds 213 
to IRF9 and inhibits the transcriptional activity of the ISGF3 enhanceosome made of IRF9, STAT1 214 
and STAT2 (6, 7). Thus, altogether, E6 and E7 block both the activation of the type I IFN gene 215 
and the IFN activation of the innate antiviral immunity as shown by the severe down regulation of 216 
IFN-responsive genes (85). Last but not least, since apoptosis induced by IFN-α/β depends upon 217 
p53 (97), the E6-mediated degradation of p53 further contributes to prevent death of the virus 218 
infected cells. 219 
 220 
 221 
3) Herpes simplex virus ICP0: a dual E3-Ubiquitin ligase  222 
 223 
Herpes simplex virus-infected cell protein 0 (ICP0, also called vmw110) was initially 224 
described as a protein found to accumulate in infected cells, but not present in the virion. It acts 225 
as a promiscuous transactivating signal, since expression by transfection results in the activation 226 
of numerous cellular genes (see (46) for review).  227 
 228 
Gene and structure 229 
ICP0 is coded by α0 which is transcribed in several spliced mRNA subspecies. The 775 230 
aa long protein is extensively post-translationally processed and the pattern of isoform expression 231 
vary with the progress of the infection. It contains a nuclear localisation signal and a self-232 
interacting domain leading to formation of dimers and higher ordered multimers. 233 
 234 
E3 Ubiquitine ligase activity 235 
ICP0 dynamically interacts with the proteasome (121) and is the only known ubiquitin 236 
ligase protein exhibiting two independent E3 sites (47). ICP0 has a RING domain and a HUL-1 237 
domain close to its NH2 and COOH terminus respectively (FIGURE 3).  238 
The RING domain is responsible for the recruitment of both of the cellular E2 ubiquitine 239 
conjugating enzyme UbcH5a (13) and one cellular substrate, the ubiquitin-specific protease 240 
enzyme USP7 (also called HAUSP) (35).  241 
ICP0 is its own substrate for ubiquitination (16). It also directly ubiquitinates USP7 in vitro 242 
and in vivo, and, this activity leads to a reduction in cellular USP7 levels during HSV-1 infection 243 
(35). Conversely, USP7 stabilizes ICP0 in vitro and in vivo by protecting ICP0 from auto-244 
ubiquitination (16). These reciprocal activities of the two proteins mimic the USP7-mediated 245 
stability of Mdm2 (64). The outcome during productive HSV-1 infection is that the USP7-mediated 246 
stabilization of ICP0 is dominant over ICP0-induced degradation of USP7 (10).  247 
The ICP0 mediated ubiquitination of p53 is weak compared to that of Mdm2, the major 248 
cellular E3 ubiquitin ligase which keeps the p53 in low level in uninfected cells. ICP0 binds to p53 249 
by residues 241 to 594 and then promotes low levels of p53 ubiquitination in infected cells (11). 250 
 251 
Other cellular proteins targeted for proteasome-mediated degradation by the ICP0-252 
UbcH5a complex are the catalytic subunit of DNA protein kinase (DNA-PK) (93), the  centromeric 253 
proteins CENP-C and CENP-A (34, 77) and two major components of the nuclear substructure 254 
ND10, the promyelocytic leukemia antigen PML (12, 20)  and small ubiquitin-like modifier 255 
(SUMO)-modified forms of SP100 (20, 92). In cells expressing ICP0, PML can be easily 256 
destroyed, but neither PML nor its SUMO-modified forms has been successfully ubiquitinated 257 
directly in vitro by ICP0 (12). Thus an additional factor or some unknown substrate may be 258 
required to form an active E3 ligase complex for in vivo degradation of PML and/or sp100. In cells 259 
expressing dominant-negative UbcH5a, but not dominant-negative UbcH6 or UbcH7, blocks ICP0 260 
RING-mediated PML and sp100 degradation and can delay ND10 disruption by at least several 261 
hours (43). 262 
 263 
The second ubiquitin ligase domain HUL-1 within ICP0, is not a Zn-finger and is required 264 
for the ubiquitination of the E2 ubiquitin ligase UbcH3 (cdc34) (121). UbcH3 is the major E2 265 
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enzyme which forms a complex with skp1-skp2-F-box and promotes the degradation of cyclin D1 266 
and cyclin D3 (see (25) for review). ICP0 was found to stabilize both cyclins D3 and D1, without 267 
evidence for a direct interaction with cyclin D1 (121). UbcH3 strongly interacts with ICP0 20-241 268 
region, which encompasses the RING domain, and moderately to ICP0 621-625 or HUL-1 269 
domain (47). Only the latter domain and aspartate 199 are essential for ubiquitination and 270 
degradation of UbcH3, since, in cells infected with HSV-1, ICP0 with disrupted RING domain has 271 
no effect on UbcH3 degradation. Thus, N-terminus of ICP0 would indirectly contribute to the 272 
ubiquitination of UbcH3 by capturing it and pushing it towards the second ligase activity site (46). 273 
 274 
Cellular impact and counteraction of innate immunity 275 
Owing its numerous substrates and multiple molecular partnerships, ICP0 interferes with 276 
many viral and cellular functions. ICP0 with intact RING finger stimulates lytic infection and 277 
reactivates quiescent HSV-1 viral genomes (see (46) for review). HSV-1 mutants devoid of ICP0 278 
are less cytotoxic and less pathogenic. Disruption of kinetophore due to polyubiquitination of 279 
CENP subunits by ICP0 results in abnormal chromosome segregation, unusual cytokinesis, and 280 
nuclear morphological aberrations: cells become stalled at an unusual stage of mitosis defined as 281 
pseudoprometaphase (34, 54, 76). However, the impact of ICP0-mediated UbcH3 degradation 282 
and resulting cyclin D1 and D3 stabilization remains unclear in HSV infected cells (33). 283 
 ICP0 is clearly involved in the dampening of the (i) development of antiviral state and (ii) 284 
the amplification through the IFNÙIFNAR pathway.   285 
(i) During infection by HSV-1, there is little expression of interferon stimulated genes 286 
(ISGs), whereas cells infected by mutant ICP0null HSV-1 exhibit high level of ISG expression (32). 287 
A significant part of this ISG expression is likely independent from the elicited IFN response since 288 
it is insensitive to a protein synthesis inhibitor (82, 87, 99). ICP0 acts by inhibiting IRF-3-mediated 289 
activation of ISGs (69, 81). This inhibition critically relies on intact RING domain and active 290 
proteasome-dependent proteolysis (32, 69). IRF-3 turn-over is increased and nuclear 291 
accumulation of IRF-3 is blocked by ICP0 (81), but ICP0 does not induce the degradation of 292 
TBK1, IRF-3, IRF-7, or CBP which all belong to the IRF-3 signalling pathway (69).  293 
(ii) While wild type HSC-1 is relatively insensitive to exogenous interferon α/β treatment 294 
of host cells, the growth of ICP0null HSV-1 is inhibited in Vero cells pretreated by type I interferon 295 
(49, 83, 84). Moreover, mutant ICP0null HSV-1 poorly replicates in mice, a phenotype which is 296 
reverted in IFNAR-/- mice (63).  297 
How does E3 ubiquitin ligase activity of ICP0 can contribute or even be responsible for 298 
the ICP0 blocks of the induction of an antiviral state ? 299 
(1) The ICP0 mediates the degradation of PML which is required for the interferon response. 300 
Indeed, exogenous IFN does not induce an efficient antiviral state in PML-/- cells and does not 301 
affect the growth of ICP0null HSV-1 in these cells (19). Interestingly, CBP/p300, which are 302 
subunits of the enhanceosome downstream to the IRF-3 pathway, bind to PML (106) and their 303 
nuclear distribution is strongly modified in HSV-1 infected cells provided that ICP0 with an intact 304 
RING domains is expressed (69). 305 
(2) DNA-PK stabilizes IRF-3 (60), and ICP0-mediated targeting of DNA-PK for degradation may 306 
contribute to the weakening the IRF-3 activation pathway. 307 
(3) P53 is up-regulated by IFN to mediate apoptotic signal (97). ICP0 mediated targeting for 308 
degradation of p53 can contribute to the resistance of HSV to IFN. 309 
 In conclusion, ICP0 is an E3 Ubiquitin ligase which targets several cellular proteins, some 310 
of them being involved in the cellular innate immunity. We propose that the potent anti-innate 311 
immunity properties of ICP0 results from the coordinate disruption of several innate immunity 312 
pathways. Furthermore, at a late stage of HSV-1 infection, ICP0 prevents the degradation of 313 
rRNA according to a new antiviral mechanism distinct from the IFN-induced RNAse L pathway. 314 
This effect, however, does not requires an intact RING domain (111). 315 
 316 
 317 
4) Adenovirus E4orf6 and E1B55K protein: substrate recruiting sub-units of an E3 ligase  318 
 319 
Human adenovirus has evolved strategies to regulate cellular proteins function to permit 320 
efficient viral replication. The viral E1B-55K/E4orf6 ubiquitin ligase is also required for efficient 321 
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viral late protein synthesis in many cell types, but the mechanism is not understood. 322 
 323 
Genes and structures  324 
E4orf6 and E1B55K are two genes expressed early after adenovirus infection. They 325 
encoded a 34 kDa and 55 kDa proteins, respectively. E4orf6 belongs to the virus genes involved 326 
in the virus transcription and cell cycle control and E1B55K participates in inhibiting apoptosis.  327 
 328 
E3 ligase activities 329 
In productively infected cells, adenovirus E4orf6 and E1B55K redirect the cellular E3 330 
ligase complex made of RING protein Rbx1/Roc1, Cullin 5, Elongin B and C (FIGURE 4) to target 331 
p53 for polyubiquitination and degradation (1, 18, 48, 100-102, 112) (see also (8, 105) for review). 332 
Infection with mutant viruses that do not express either E1B55K or E4orf6 proteins does not 333 
induces p53 degradation (112). E4orf6/E1B55K E3 ligase complex is remarkably similar to the 334 
Von Hippel-Lindau tumor suppressor and SCF (skp-Cul1) E3 ubiquitin ligase complex. Rbx1 335 
interacts with E4orf6 but not with E1B55K (100), and looks acting as a substrate specificity factor. 336 
This complex interacts with the E2-conjugating enzyme UbcH3 to conjugate ubiquitin chains to its 337 
substrates. E1B55K is the substrate recognition subunit of this complex. Both E4orf6 and 338 
E1B55K contain putative BC-box, but only E4orf6 directly interacts with Elongin C via its BC-Box 339 
motif. Furthermore, E1B55K also does not bind stably to isolated E4orf6 and requires E4orf6 to 340 
be in complex with Cul5 and Elongins B and C. The formation of the complex is thought to alter 341 
the conformation of E4orf6 and stabilize the interaction between E4orf6 and E1B55K (9). E4orf6 342 
and E1B 55K bind p53 near its N and C termini, respectively. The ligase complex activity is also 343 
critical dependent on NEDD8 which modifies the activity of Cullin5 (90, 100, 102). The E2 344 
conjugating enzyme UbcH3 (cdc34) is associated with E4orf6 in vivo, and, in an in vitro 345 
ubiquitination test, UbcH5 acts as a functional E2 enzyme (100).  346 
E1B55K/E4orf6-Elongins B/C/Cullin5/Rbx1 E3 ligase complex can target one or more 347 
subunits of the MRN complex involved in DNA double-strand break repair for proteasome-348 
mediated degradation (114), although there is no direct evidence for MRN single subunits to be 349 
polyubiquitinated. E1B55K/E4orf6/elonginBC/Cullin5/Rbx1 also exploits the cellular aggresome 350 
response to accelerate the degradation of MRN complexes in adenovirus-infected cells (74). 351 
Aggresome formation may contribute to protect the viral genomic DNA from MRN activity by both 352 
sequestering MRN in the cytoplasm and dramatically promoting its degradation by the 353 
proteasome. 354 
During the late phase of infection by adenovirus, E1B55K/E4orf6 complex promotes the 355 
nuclear export of viral mRNA and prevents that of cellular mRNAs (see (8) for review). Does the 356 
E1B55K/E4orf6 E3 ligase complex also target a mRNP protein involved in most cellular mRNA 357 
nuclear export and enhances export and translation of late viral mRNA (8) ?  358 
E4orf6 can interact with p53 and inhibit its transactivating activity (18, 28). In the absence 359 
of E4orf6, E1B55K dramatically increases the concentration of p53 (79). But p53 transactivating 360 
activity is blocked. Possibly, upon interaction with p53, E1B55K bring a repression domain close 361 
to the p53 activating domain (8). E1B5K also inhibits the acetylation of p53 by PCAF and thus 362 
contributes to p53 inhibition by another mechanism (73).  363 
 364 
Cellular impact and counteraction of innate immunity 365 
Adenoviruses have developed several genes to control the antiviral effect of innate 366 
immunity (see (14) for review). Lowering the p53 contents of the cell by E4orf6 and E1B 55K 367 
proteins likely contributes to protect the infected cells from IFN induced p53-dependent apoptosis 368 
(97). Furthermore, by blocking nuclear export of cellular mRNA, they may have a major impact on 369 
the expression of IFN and ISG genes. 370 
 371 
 372 
5) Lentivirus VIF protein: a substrate recruiting sub-unit of an E3 ligase  373 
 374 
The viral infectivity factor VIF encoded by HIV-1 and most other lentivirus was initially 375 
found in the nineties to be required for replication in “non permissive” cells such as primary T cells 376 
and macrophage but dispensable for replication in epithelial cell lines. More than ten years later, 377 
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the cellular target APOBEC3G was identified (see (104) for review). 378 
 379 
Gene and structure 380 
VIF is coded within the region on an alternative codon frame and has a size of about 23 381 
kDa. Functionally, VIF shared many features with the adenoviral E4orf4 protein. 382 
 383 
E3 ligase activities 384 
VIF contains a BC-like-box (or SOCS-Box) (126, 128) to recruit Elongin C/B (FIGURE 5). 385 
Binding to Elongin-C is negatively regulated by serine phosphorylation of the BC-box (80). VIF 386 
does not have a Cul-Box, but contains a HCCH motif (Hx5Cx17-18Cx3-5H), with potency to 387 
coordinate a zinc atom, the integrity of which is required for binding to Cullin 5 (78), In addition it 388 
binds to the RING containing Rbx1 E3 ligase subunit (126). Vif connects the APOBEC3G and 389 
APOBEC3F (apolipoprotein B mRNA-editing enzyme) as a substrate to the multisubunit E3 ligase 390 
for polyubiquitination and degradation (71, 126). The active E2 ligase recruited by the RING 391 
domain of Rbx1 has not been defined in vivo, although Ubc12 and Ubc5A can work in vitro. The 392 
loss of function of VIF mutants correlates with their inability to bind to APOBEC3G or to give rise 393 
to functional E3 ligase (61). VIF is also autoubiquitinylated by the same E3 ligase complex which 394 
explains is short half-life in vivo (40, 71, 80). Overexpression of APOBEC3G stabilizes Vif 395 
expression as if the two substrates compete with each other (71). Thus, VIF functions like an F-396 
box protein by bringing together the Cul5 complex and the substrate.  397 
Surprisingly, APOBEC3G is also monoubiquitinated by the unimolecular HECT-type E3 398 
ligase Nedd4.1, for its efficient packaging within budding virions (30). Thus, APOBEC3G is the 399 
substrate for both monoubiquitination and polyubiquitination by two separate E3 ligases.  400 
Besides targeting APOBEC3G for ubiquitination and degradation, VIF may also directly 401 
inhibit its deaminase activity, as suggested in experiments performed in E. Coli (108). 402 
 403 
Cellular impact and counteraction of innate immunity 404 
 APOBEC3G is a cytidine deaminase which deaminates cytidine to uracil, resulting in 405 
deleterious overmutagenesis of the HIV-1 genome. Furthermore, APOBECG3G displays another 406 
anti-HIV-1 activity which is independent from its cytidine deaminase activity (86). Vif activity is a 407 
species-specific factor because it cannot recognize APOBEC3G from other species which differ 408 
by a single residue within the binding site (D128K) (71). This intrinsic cellular immunity belongs 409 
also to the inducible innate immunity since a type I IFN treatment can upregulate the APOBEC3G 410 
expression (118). 411 
 412 
 413 
6) Rubulavirus V proteins: a substrate recruiting sub-unit of an E3 ligase  414 
 415 
Rubulavirus are enveloped RNA viruses whose replication occurs entirely within the 416 
cytosol. Their genome code for less than ten proteins, nevertheless because they also have to 417 
cope with the cellular innate immunity, at least one of them, V protein, is a potent inhibitor of the 418 
interferon system. As adenovirus EE4orf6 and Vif, V protein acts a scaffold linking a multi-subunit 419 
cellular E3 ligase to new cellular substrates. 420 
 421 
Gene and structure 422 
Members of the Rubulavirus genus (simian virus 5 -SV5-, human parainfluenza virus 2 -423 
hPIV2- and mumps virus) which belongs to the Paramyxoviridae family and Monogavirales order 424 
have a negative strand RNA whose genome contains 7 genes coding for 8 proteins. Indeed the 425 
second gene codes the P protein, a polymerase cofactor, and, upon editing of P mRNA, to V 426 
protein. V is two hundred amino acid long, shares a common N sequence with P and has a minor 427 
C-terminus rich in Cys residues, a hallmark of all Mononegavirales V protein. This C-terminus is a 428 
new Zn-finger with no homology with other known Zn-finger structures (66). 429 
 430 
E3 ligase activities 431 
Rubulavirus V proteins were initially characterized for their ability to bind to the highly 432 
conserved UV-damaged DNA-binding protein DDB1 protein (68) (FIGURE 6). DDB1 has a 433 
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multipropeller structure associating three β-propellers called BPA, BPB and BPC and one C-434 
terminal helical domain (66). SV5 V binds to the BPA-BPC double propeller pocket by inserting its 435 
N-terminal helix, while the Zn-finger does not interact with DDB1. The BPC propeller DDB1 docks 436 
to the N-terminus of the E3 ligase Cul4A scaffold (66). Cul4A can recruit the Rbx1 RING protein 437 
(or another protein ?) which in turns recruits a yet to be defined E2 ligase. Mumps V protein binds 438 
also to this later protein (120). V proteins from SV5, mumps and hPIV2 multimerize and bind to 439 
STAT2. A single residue (Asn100 in V from SV5) located in a β−sheet determined efficient 440 
binding to STAT2 (66, 125). Only hPIV2 V can directly target STAT2 as an ubiquitination 441 
substrate, although V from SV5 can do so in vitro (98, 120). Instead, STAT2 is used by V proteins 442 
from SV5 and mumps as a scaffold to recruit STAT1 which is polyubiquitinated and degraded by 443 
the proteasome (3, 27, 119). Mumps V can also recruit directly STAT3 for ubiquitination and 444 
degradation, the later process for which the recruitment of Rbx/Roc1 is required (120) 445 
.  446 
Cellular impact and counteraction of innate immunity 447 
STAT1-STAT2 heterodimers associated with IRF9 constitute the critical transactivating 448 
complex downstream the signalling induces by IFN binding to IFNAR. By downregulating STAT1, 449 
V protein is predicted to render mumps, SV5 and hPIV2 viruses less sensitive to IFN-mediated 450 
antiviral effect. Indeed, the inability of V protein to target mouse STAT1 correlated well with the 451 
very poor replication of SV5 in mice, whereas STAT1-/- mice are sensitive to viral infection (see 452 
(51) and references herein).  453 
However, in vitro, the phenotype of recombinant SV5 virus with C-truncated V protein is 454 
complicated, because V exhibits many other functions. (i) It binds to MDA5 (melanoma 455 
differentiation-associated gene 5), a companion molecule of the RIG-I-dependant IFN-β activation 456 
pathway (2, 51). (ii) V acts as an anti-apoptotic factor (115). Interestingly, all these functions 457 
require an intact Zn-finger. (iii) In a minigenome replication model, V protein exhibits transcription 458 
and replication inhibition properties (70).  459 
The functional impact of STAT3 degradation by mumps V protein remains to be clarified 460 
since the role of STAT3 is variable according to the cell type (113). 461 
 462 
 463 
Conclusion 464 
 465 
We have illustrated, in this review, the various strategies used by viruses to hijack the 466 
ubiquitination pathway and target cellular proteins for degradation (or disrupting their function ?) 467 
in order to evade cellular innate antiviral response. Can a virus act also by inhibiting cellular 468 
ubiquitination ? The answer is probably yes, as revealed by the ability of measles virus P protein 469 
to inhibit ubiquitination and stabilize the RING-type E3 ligase PIRH2 protein (a homolog of 470 
MDM2), although the physiological relevance of this observation remains to be uncovered (22). 471 
This short survey has brought a glimpse of what we predict will be an increasing area of 472 
knowledge, namely the subversion or the use of ubiquitination and related peptide conjugation 473 
such as sumoylation and ISGylation by viruses to adapt their cell host for optimal replication and 474 
survival in the context of a whole organism and population. Indeed, there are numerous cellular 475 
E3 ligases, some of which are upregulated by type I IFN (88), and beside the dozen of cellular 476 
proteins so far identified as antiviral weapons, there are likely many other cellular proteins which 477 
can exhibit non specific or specific antiviral activities. For example, one of the gene is ISG15 478 
which is an ubiquitin-like protein, that, on one hand, targets the release of HIV-1 (91), and, on 479 
another hand, has its conjugation property inhibited by the Influenza B virus NS1 protein (129).  480 
 481 
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FIGURE legends 483 
 484 
FIGURE 1. Intrinsic catalytic E3 ligase activity of KSV RTA protein.  485 
 486 
FIGURE 2. E6-AP independent (upper) and E6-AP dependent E3 ligase activity of HPV E6 487 
protein, known substrates (dot lined), binding (full lined) partners and possible effect on innate 488 
immunity. For symbols see FIGURE. 1. 489 
 490 
FIGURE 3. Current view of E3 ligase activity of HSV ICP0 protein: known substrates and possible 491 
effect(s) on cellular functions. The molecular support for the recruitment of sp100, PML, CENP-492 
A/C and DNA-PK as the substrates for ICP0 E3 ligase activity is yet unknown. For symbols see 493 
also FIGURE. 1. 494 
 495 
FIGURE 4. E3 ligase activity of adenovirus E4orf6 and E1B55K proteins. E1B55K is stably bound 496 
to E4orf6 only when the latter is in complex with Cullin 5 and Elongins B/C. For symbols see 497 
FIGURE. 1. 498 
 499 
FIGURE 5. E3 ligase activity of HIV-1 Vif protein resulting in self and APOBEC-3G 500 
polyubiquitination. Vif is also monoubiquitinated by HECT-type E3 ligase Nedd4-1 which results in 501 
the efficient Vif encapsidation into virions. For symbols see FIGURE. 1. 502 
 503 
FIGURE 6. E3 ligase activity of Rubulavirus V protein. Mumps V interacts directly with 504 
Roc1/RBX1, and recruit STAT3 as ubiquitination substrate. Mumps and SVF5 interacts with 505 
STAT2 solely to recruit STAT1 as the ubiquitination substrate. HIPV2-V protein binds and targets 506 
STAT2 for ubiquitination. Roc1/RBX1 looks dispensable for STAT1 or STAT2 ubiquitination by 507 
any V protein. For symbols see FIGURE. 1. 508 
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